- A hospital's account of an international patient's treatment can show that a cross-border pathway existed in that case; it does not show that the same medicine or pathway is right for another person.
- Availability in one country is not proof of a patient's eligibility, current regulatory status, clinical benefit, cost, speed of access or insurance coverage.
- For complex cancer care, patients need provider-specific answers on indication, evidence, risks, monitoring, alternatives and follow-up before arranging travel.
What the hospital report says
In a September 21 article about its participation in the WTO Public Forum, Jiahui Health described two international patient journeys and its cross-border care services. One account concerns a U.S. patient with non-small-cell lung cancer who travelled to Shanghai for ivonescimab after discussions with a clinician in the United States. The hospital says the patient developed a serious immune-related adverse event and required intensive care, after which it convened multidisciplinary consultations and maintained contact with the U.S. medical team. This is a first-party hospital account, not an independent treatment recommendation or a general eligibility standard.
Do not turn a news report into a treatment decision
The article's description of a medicine as available only in China is a report of that hospital's statement at that time. It does not establish the medicine's current status for every indication, whether it is available at another institution, whether it is appropriate for a particular tumour, or whether a patient can receive it. Individual treatment choices require a responsible clinician's assessment of diagnosis, prior therapy, pathology, overall condition, risks and alternatives. China Med Links does not recommend cancer treatments, determine eligibility or promise access to a named medicine.
Ask the treating hospital the right clinical questions
Before making travel arrangements, ask the intended provider to explain the current intended indication, the basis on which it would assess eligibility, the expected treatment setting, likely monitoring, known serious risks, alternatives and what information it needs for review. Ask whether the proposed route is routine clinical care, a trial or another regulated access pathway, and request the provider's current written explanation rather than relying on a media summary. Keep the clinician managing care at home involved in the discussion wherever possible.
A serious complication changes the travel plan
The account itself illustrates why a cross-border plan needs more than an appointment letter. A patient should ask who manages an acute adverse event, what type of facility and specialty support is available, whether a companion may be needed, how long it may be unsafe to fly, which records will be released and how clinicians at home will receive a handover. No coordinator can guarantee a clinical course, hospital admission or fitness to travel after treatment; those decisions belong to the responsible clinical team.
Separate medical review from payment and insurance
The hospital article lists insurance direct billing among the services international patients may require, but it does not confirm coverage for any individual insurer, diagnosis or medicine. Ask the hospital and insurer separately about self-pay estimates, deposits, pre-authorization, exclusions, documentation, reimbursement and what happens if the clinical plan changes. Do not infer coverage from the existence of a direct-billing service or from another patient's reported journey.
Build a continuity plan before departure
For a complex oncology enquiry, prepare pathology reports, molecular testing where available, treatment history, imaging reports and image files, current medicines and a focused question for the receiving specialist. Decide in advance how results, discharge summaries and treatment details will reach the clinician at home. A non-clinical coordinator can help organize records, translation logistics, appointments and local practical support after the provider confirms the route, but cannot interpret results or take responsibility for clinical follow-up.
Sources
- Jiahui Health: inbound medical tourism experience at the WTO Public Forum 2026 →
- China Med Links: cancer second opinion questions in China →
- China Med Links: cancer care in China, records and review →
- China Med Links: follow-up care after returning home →
See our Sources & Corrections Policy.
Unless explicitly stated, cases discussed here come from public reporting and did not involve our services. This article is general information, not medical, legal or immigration advice.